A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.

Trial Details

NCT ID
NCT07578571
Phase
PHASE1
Sponsor
Immunome, Inc.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • IM-1617
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Irving, Texas, United States|32.81402,-96.94889

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:
  • CRC, all subtypes
  • Non-squamous cell carcinoma subtypes, such as adenocarcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →